The Cure Starts Now follows an extensive grant approval process to ensure your dollars make the biggest impact to homerun cancer research. Take comfort in knowing that The Cure Starts Now only funds: research that follows our mission, research that is non-duplicative, and research that is financially sound.


The Cure Starts Now has funded $24,934,877 (USD) in pediatric brain cancer research in partnership with the DIPG / DMG Collaborative. This includes 161 grants at over 100 hospitals in 29 countries.




Children's Healthcare of Atlanta – $100,000

Amount
$100,000.00
Date
November 2024

Radiation Resistance in Medulloblastoma

University of Texas Health Science Center at San Antonio – $100,000

Amount
$100,000.00
Date
November 2024

Targeting Metabolic Vulnerabilities for Treating Medulloblastoma

University of Texas Health Science Center at San Antonio – $50,000

Amount
$50,000.00
Date
November 2024

Targeting RRNA Modification and SNORNA Function, A Novel Concept to Treat Aggressive Medulloblastoma

Children’s National Medical Center – $300,000

Amount
$300,000.00
Date
November 2024

Multilamellar H3K27M RNA aggregates targeting diffuse midline glioma, including diffuse intrinsic pontine glioma.

Children's Hospital Los Angeles – $100,000

Amount
$100,000.00
Date
October 2024

Targeting FOXR2 in Diffuse Midline Gliomas

University Hospital of Navarra - $100,000 USD, €92,637 EUR

Amount
$100,000.00
Date
October 2024

Targeting Diffuse Midline Glioma vulnerabilities as a therapeutic strategy.

The Institute of Cancer Research – $111,445 USD / £85,976 GBP

Amount
$111,445.00
Date
October 2024

Unravelling transcriptional plasticity as a non-genetic mechanism of drug resistance in DMG.

Children’s Cancer Institute – $100,000 USD / $150,589 AUD

Amount
$100,000.00
Date
October 2024

Targeting lactate production pathways as a novel therapy against DIPG

Sydney Children's Hospital - Randwick – $196,577 USD / $296,025.11 AUD

Amount
$196,577.00
Date
October 2024

Unlocking the potential of the blood-brain barrier in the fight against paediatric brain gliomas.

McGill University - $100,000

Amount
$100,000.00
Date
October 2024

Understanding tumor heterogeneity and characterizing treatment responses in ACVR1-mutated diffuse midline gliomas.

Cincinnati Children’s Hospital Medical Center - $200,000

Amount
$200,000.00
Date
October 2024

Combining FLASH and immunotherapy to target medulloblastoma relapse

Emory University / Cincinnati Children's Hospital – $93,250

Amount
$93,250.00
Date
March 2024

SUMOylation as a novel therapeutic target in DIPG

University of Chicago Medical Center / Washington University St. Louis – $100,000

Amount
$100,000.00
Date
December 2023

Characterizing and Targeting ABL1 and ABL2 in Medulloblastoma Leptomeningeal Dissemination.

Icahn School of Medicine at Mount Sinai – $100,000

Amount
$100,000.00
Date
December 2023

Targeting macrophages to improve the survival of DIPG

Children’s Cancer Institute – $50,000

Amount
$50,000.00
Date
December 2023

A novel formulation to allow the simultaneous targeting of MYCN expression and copper chelation to treat DIPG tumour and overcome multidrug resistance.